Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Otsuka Holdings Company ADR (OP:OTSKY)

22.04 +0.00 (+0.01%)
Streaming Delayed Price Updated: 10:03 AM EDT, Jul 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Otsuka Holdings Company ADR

Axsome Reveals Data From Alzheimer's Studies, Analyst Sees Hope Despite Mixed Trial Results
Axsome's AXS-05 met endpoints in Alzheimer's agitation studies, showing long-term safety and tolerability. FDA filing planned for late 2025. 
Via Benzinga
OTSKY Stock Earnings: Otsuka Holdings Reported Results for Q2 2024
Otsuka Holdings just reported results for the second quarter of 2024. 
Via InvestorPlace
OTSKY Stock Earnings: Otsuka Holdings Reported Results for Q1 2024
Otsuka Holdings just reported results for the first quarter of 2024. 
Via InvestorPlace
IGC Pharma Says Cannabinoid-Based Drug Candidate Provides Fast Relief With Fewer Side Effects For Alzheimer's-Associated Agitation
IGC Pharma shares encouraging interim data from Phase 2 trial of IGC-AD1 for Alzheimer's agitation. Results suggest significant reduction in agitation with minimal side effects compared to placebo. 
Via Benzinga
Alzheimer's-Focused Small Cap Firm IGC Pharma Releases Data, Candidate Reduces Agitation Compared To Placebo
IGC Pharma unveils interim results of Phase 2 trial of IGC-AD1 for Agitation in Alzheimer's Dementia. Shows reduction in agitation vs. placebo observed. 
Via Benzinga
Akebia's Anemia Drug Disappoints In Mid-Stage COVID-19 Study
Via Benzinga
Why Are Akebia Therapeutics Shares Falling Today?
Via Benzinga
FDA Rejects Akebia Therapeutics' Vadadustat For CKD-Associated Anemia
Via Benzinga
Regulatory Setback For Medtronic's High Blood Pressure Device - FDA Backed Japanese Firms' Similar Device For Uncontrolled Hypertension
Medtronic Plc (NYSE: MDT) says the FDA Circulatory System Devices Panel (CSDP) voted unanimously (13-0) on safety and in favor (7-6) of the effectiveness of the Symplicity blood pressure procedure,  
Via Benzinga
Individuals With Uncontrolled Hypertension - FDA Adcomm Panel Just Supported Japanese MedTech's Blood Pressure Treatment Device
The FDA's Circulatory Systems Devices Panel of the Medical Devices Advisory Committee backed Recor Medical Inc and its parent company, Otsuka Medical Devices Co Ltd's 
Via Benzinga
Japan's Otsuka Pharma-Lundbeck Partnered Depression Drug Gets FDA Approval For Alzheimer's Agitation
Otsuka Pharmaceutical Co Ltd (OTC: OTSKF) (OTC: OTSKY) (Otsuka) and H. 
Via Benzinga
Targeting Autosomal Dominant Polycystic Kidney Disease With Novel Approaches
Approximately 160,000 individuals in the United States are diagnosed with polycystic kidney disease, and the global prevalence of the condition is estimated at between 4 million and 7 million people. 
Via Benzinga
The Daily Biotech Pulse: FDA Wants Omicron-Targeted COVID-19 Boosters, Provention Bio Clears Hits Hurdle For Diabetes Prevention Drug, Oxford Biomedica, AstraZeneca Strike Vaccine Pact
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Has A Sugar Daddy Emerged In The Psychedelic Drug Industry?
One very large drug multinational has already been active in writing checks to finance drug development in the psychedelic drug industry. 
Via Talk Markets
4 Pre-Merger SPACs to Buy That Are Poised to Soar
From quantum computing to energy storage, these four SPACs' merger partners could prove to be quite disruptive over the longer term. 
Via InvestorPlace
Topics Electric Vehicles
Akebia Therapeutics Stock Jumps as FDA Accepts Vadadustat US Application in CKD-Related Anemia
Akebia Therapeutics Inc (NASDAQ: AKBA) and its collaborator Otsuka Holdings (OTC: OTSKY) have announced that the FDA has accepted to review vadadustat... 
Via Benzinga
3 Cheap Pharmaceutical Stocks to Grab Now
The pharmaceutical industry has been the beneficiary of significant investor attention amid the COVID-19 pandemic as society turned to its products to fight the coronavirus. 
Via Talk Markets
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.